Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This randomized phase II trial is studying how well giving pazopanib with or without bicalutamide works in treating patients with prostate cancer that did not respond to hormone therapy. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Giving pazopanib hydrochloride together with bicalutamide may be an effective treatment for prostate cancer.
Full description
PRIMARY OBJECTIVES:
I. To determine the therapeutic activity of GW786034 (pazopanib hydrochloride) with and without bicalutamide in the treatment of hormone-refractory prostate cancer using prostate specific antigen (PSA)-response rate.
SECONDARY OBJECTIVES:
I. To estimate objective tumor response in patients with measurable disease. II. To estimate the median time to progression. III. To investigate the safety and tolerability of GW786034 with and without bicalutamide.
IV. To estimate the median duration of PSA-response. V. To determine the steady state levels of GW786034 with and without bicalutamide.
VI. To investigate the correlation between prior exposure to bicalutamide and non-steroidal anti-androgens with response and survival outcomes.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28.
ARM II: Patients receive pazopanib hydrochloride PO QD on days 1-28. Patients also receive bicalutamide PO QD on days 8-28 of course 1 and on days 1-28 in all subsequent courses.
Courses in both arms repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 4 weeks for 12 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Histologically or cytologically confirmed prostate cancer
Must have received prior hormonal therapy, including either medical (luteinizing hormone-releasing hormone [LHRH] agonist) or surgical (orchiectomy) castration
Must have radiological documentation of either measurable or non-measurable disease
Must show documented progression of prostate cancer while on hormonal therapy as indicated by PSA increase
PSA >= 5 ng/mL
No known brain metastases
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 OR Karnofsky PS 60-100%
Life expectancy > 3 months
White blood cell (WBC) >= 3,000/mm^3
Absolute neutrophil count (ANC) >= 1,500/mm^3
Platelet count >= 100,000/mm^3
International normalized ratio (INR) =< 1.2
Activated partial thromboplastin time (PTT) =< 1.2 times upper limit of normal (ULN)
Bilirubin normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 times ULN
Creatinine normal OR creatinine clearance >= 60 mL/min
Fertile patients must use effective contraception
No history of allergic reactions attributed to compounds of similar chemical or biological composition to pazopanib hydrochloride or bicalutamide
Proteinuria =< 1+ on 2 consecutive dipsticks taken >= 1 week apart
QTc < 480 msec
No significant electrocardiogram (ECG) abnormalities
No poorly controlled hypertension (systolic blood pressure [BP] > 150 mm Hg or diastolic BP > 90 mm Hg)
No condition (e.g., gastrointestinal [GI] tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation; prior surgical procedures affecting absorption; or active peptic ulcer disease) that impairs the ability to swallow and retain pazopanib hydrochloride tablets
No serious or nonhealing wound, ulcer, or bone fracture
No abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within the past 28 days
No cerebrovascular accident within the past 6 months
No myocardial infarction, cardiac arrhythmia, admission for unstable angina, cardiac angioplasty, or stenting within the past 12 weeks
No venous thrombosis within the past 12 weeks
No New York Heart Association (NYHA) class III-IV heart failure
No concurrent uncontrolled illness, including, but not limited to, ongoing or active infection
No psychiatric illness or social situation that would preclude study compliance
Recovered from all prior therapy
Prior neoadjuvant or adjuvant chemotherapy allowed
More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy
At least 4 weeks since prior antiandrogens
At least 4 weeks since prior surgery
No prior bicalutamide therapy lasting > 3 months in duration
Concurrent steroids allowed if no change in steroid dosage within the past 4 weeks
No other concurrent investigational agents
No concurrent therapeutic warfarin
No concurrent combination antiretroviral therapy for human immunodeficiency virus (HIV)-positive patients
Primary purpose
Allocation
Interventional model
Masking
23 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal